159 related articles for article (PubMed ID: 25292096)
1. Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors.
Li Y; Meng FD; Tian X; Sui CG; Liu YP; Jiang YH
Asian Pac J Cancer Prev; 2014; 15(18):7965-70. PubMed ID: 25292096
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
3. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
4. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
Heaton KM; Ju G; Grimm EA
Ann Surg Oncol; 1994 May; 1(3):198-203. PubMed ID: 7842289
[TBL] [Abstract][Full Text] [Related]
5. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
7. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
8. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
Horton SA; Oldham RK; Yannelli JR
Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
[TBL] [Abstract][Full Text] [Related]
9. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
Fujiwara T; Grimm EA
J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
[TBL] [Abstract][Full Text] [Related]
11. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
12. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
13. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2.
Heaton KM; Grimm EA
Hum Immunol; 1995 Mar; 42(3):274-80. PubMed ID: 7759316
[TBL] [Abstract][Full Text] [Related]
15. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
16. Lysis of autologous human macrophages by lymphokine-activated killer cells: interaction of effector cell and target cell conjugates analyzed by scanning electron microscopy.
Streck RJ; Helinski EH; Ovak GM; Pauly JL
J Leukoc Biol; 1990 Sep; 48(3):237-46. PubMed ID: 2391448
[TBL] [Abstract][Full Text] [Related]
17. Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: participation of both T cells and NK cells in the killing.
Parajuli P; Nishioka Y; Nishimura N; Singh SM; Hanibuchi M; Nokihara H; Yanagawa H; Sone S
J Leukoc Biol; 1999 Jun; 65(6):764-70. PubMed ID: 10380897
[TBL] [Abstract][Full Text] [Related]
18. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
19. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
20. Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells.
Shimizu Y; Kuroki T; Shiomi S; Kobayashi K; Monna T
J Gastroenterol Hepatol; 1991; 6(5):485-90. PubMed ID: 1657242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
